JP2024525150A - 置換ピロロ［２，３－ｄ］ピリミジン類、それらの製造及びそれらの治療適用 - Google Patents

置換ピロロ［２，３－ｄ］ピリミジン類、それらの製造及びそれらの治療適用 Download PDF

Info

Publication number
JP2024525150A
JP2024525150A JP2023577130A JP2023577130A JP2024525150A JP 2024525150 A JP2024525150 A JP 2024525150A JP 2023577130 A JP2023577130 A JP 2023577130A JP 2023577130 A JP2023577130 A JP 2023577130A JP 2024525150 A JP2024525150 A JP 2024525150A
Authority
JP
Japan
Prior art keywords
group
groups
methyl
pyrazol
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023577130A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525150A5 (https=
Inventor
パトリック・ベルナルデリ
ステファニー・デプレッツ
ローラン・デュボワ
ジョン・マコール
フレデリク・プチ
コリンヌ・テリエ
マーク・ビアンキオット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP21315095.6A external-priority patent/EP4105218A1/en
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2024525150A publication Critical patent/JP2024525150A/ja
Publication of JP2024525150A5 publication Critical patent/JP2024525150A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
JP2023577130A 2021-06-15 2022-06-14 置換ピロロ［２，３－ｄ］ピリミジン類、それらの製造及びそれらの治療適用 Pending JP2024525150A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21315095.6 2021-06-15
EP21315095.6A EP4105218A1 (en) 2021-06-15 2021-06-15 Substituted pyrrolo[2,3-d] pyrimidines, their preparation and their therapeutic application
EP22315117 2022-06-02
EP22315117.6 2022-06-02
PCT/EP2022/066231 WO2022263472A1 (en) 2021-06-15 2022-06-14 Substituted pyrrolo[2,3-d]pyrimidines, their preparation and their therapeutic application

Publications (2)

Publication Number Publication Date
JP2024525150A true JP2024525150A (ja) 2024-07-10
JP2024525150A5 JP2024525150A5 (https=) 2025-06-12

Family

ID=82214141

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023577130A Pending JP2024525150A (ja) 2021-06-15 2022-06-14 置換ピロロ［２，３－ｄ］ピリミジン類、それらの製造及びそれらの治療適用

Country Status (11)

Country Link
US (1) US20240383901A1 (https=)
EP (1) EP4355748A1 (https=)
JP (1) JP2024525150A (https=)
KR (1) KR20240021910A (https=)
AU (1) AU2022294022A1 (https=)
BR (1) BR112023025042A2 (https=)
CA (1) CA3223786A1 (https=)
CO (1) CO2024000083A2 (https=)
IL (1) IL309195A (https=)
MX (1) MX2023015016A (https=)
WO (1) WO2022263472A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025141029A1 (en) * 2023-12-27 2025-07-03 Sanofi Substituted pyrrolo[2,3-d]pyrimidines, their preparation and their therapeutic application
KR20250163526A (ko) 2024-05-14 2025-11-21 김성우 음전하 증폭장치가 장착된 어싱용 발판

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015512434A (ja) * 2012-04-03 2015-04-27 サノフイ 新規なチエノピリミジン誘導体、その製造のための方法およびその治療的使用
WO2017087905A1 (en) * 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
JP2018513214A (ja) * 2015-04-17 2018-05-24 チャンジョウ ロングテラ ファーマシューティカルズ インクＣｈａｎａｇｚｈｏｕ Ｌｏｎｇｔｈｅｒａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ 新規なキナーゼ阻害剤の調製と使用
JP2018537502A (ja) * 2015-12-16 2018-12-20 サウザーン リサーチ インスチチュート ピロロピリミジン化合物、キナーゼｌｒｒｋ２阻害剤としての使用、及びその調製方法
WO2020092136A1 (en) * 2018-10-31 2020-05-07 Merck Sharp & Dohme Corp. N-heteroaryl indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
WO2020149715A1 (ko) * 2019-01-18 2020-07-23 주식회사 보로노이 피롤로피리딘 유도체 및 단백질 키나아제 관련 질환의 예방 또는 치료에서의 사용을 위한 이의 용도
US20200239474A1 (en) * 2017-02-22 2020-07-30 Daegu-Gyeongbuk Medical Innovation Foundation Pyrrolo-pyrimidine derivative compound, preparation method therefor, and pharmaceutical composition comprising same compound as effective ingredient for preventing or treating protein kinase-related disease

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015512434A (ja) * 2012-04-03 2015-04-27 サノフイ 新規なチエノピリミジン誘導体、その製造のための方法およびその治療的使用
JP2018513214A (ja) * 2015-04-17 2018-05-24 チャンジョウ ロングテラ ファーマシューティカルズ インクＣｈａｎａｇｚｈｏｕ Ｌｏｎｇｔｈｅｒａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ 新規なキナーゼ阻害剤の調製と使用
WO2017087905A1 (en) * 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
JP2018537502A (ja) * 2015-12-16 2018-12-20 サウザーン リサーチ インスチチュート ピロロピリミジン化合物、キナーゼｌｒｒｋ２阻害剤としての使用、及びその調製方法
US20200239474A1 (en) * 2017-02-22 2020-07-30 Daegu-Gyeongbuk Medical Innovation Foundation Pyrrolo-pyrimidine derivative compound, preparation method therefor, and pharmaceutical composition comprising same compound as effective ingredient for preventing or treating protein kinase-related disease
WO2020092136A1 (en) * 2018-10-31 2020-05-07 Merck Sharp & Dohme Corp. N-heteroaryl indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
WO2020149715A1 (ko) * 2019-01-18 2020-07-23 주식회사 보로노이 피롤로피리딘 유도체 및 단백질 키나아제 관련 질환의 예방 또는 치료에서의 사용을 위한 이의 용도

Also Published As

Publication number Publication date
KR20240021910A (ko) 2024-02-19
IL309195A (en) 2024-02-01
BR112023025042A2 (pt) 2024-02-27
MX2023015016A (es) 2024-05-31
AU2022294022A1 (en) 2024-02-01
CA3223786A1 (en) 2022-12-22
CO2024000083A2 (es) 2024-04-08
EP4355748A1 (en) 2024-04-24
WO2022263472A1 (en) 2022-12-22
US20240383901A1 (en) 2024-11-21

Similar Documents

Publication Publication Date Title
KR102354472B1 (ko) Ｊａｋ１ 저해제로서의 피페리딘­４­일 아제티딘 유도체
KR102030609B1 (ko) Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
CN117580592A (zh) 用于靶向布鲁顿酪氨酸激酶降解的化合物
KR20140019300A (ko) Ｊａｋ 억제제로서 사이클로부틸 치환된 피롤로피리딘 및 피롤로피리미딘 유도체
WO2014133022A1 (ja) テトラヒドロイミダゾ［１，５－ｄ］［１，４］オキサゼピン誘導体
MX2011001333A (es) Derivados de pirazolo [3, 4] pirimidin-4-ilo y sus usos para tratar la diabetes y obesidad.
JP2023523863A (ja) 新規大環状ｌｒｒｋ２キナーゼインヒビター
US20250333399A1 (en) Inhibitors of fibroblast growth factor receptor kinases
CN119403806A (zh) Trem2调节剂
JP2024525150A (ja) 置換ピロロ［２，３－ｄ］ピリミジン類、それらの製造及びそれらの治療適用
US12570640B2 (en) 2-aminoquinazolines as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
EP4105218A1 (en) Substituted pyrrolo[2,3-d] pyrimidines, their preparation and their therapeutic application
CN117881681A (zh) 经取代的吡咯并[2,3-d]嘧啶、其制备及其治疗应用
WO2024061118A1 (zh) 大环含氮冠醚化合物及其作为蛋白激酶抑制剂的应用
EA048670B1 (ru) Макроциклические ингибиторы lrrk2 киназы
HK1209114B (en) 3-substituted pyrazoles and use as dlk inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250604

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250604

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260224